Developer docs
API playgroundTry for free, no card

Search company profiles

VitriVax

Full company profile

uuid0002aah

Namestring
VitriVax
Legal namestring
VitriVax, Inc.
Websiteurl
vitrivaxbio.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

VitriVax is a privately held formulation technology company based in Boulder, Colorado, founded in 2014 out of the University of Colorado Boulder laboratories of co-founders Dr. Robert Garcea (virology) and Dr. Theodore Randolph (chemical engineering). The company develops and licenses a single proprietary platform — ALTA® (Atomic Layering Thermostable Antigen and Adjuvant) — that combines spray drying, which encapsulates antigens in a sugar-glass matrix, with atomic layer deposition (ALD), which coats the resulting microparticles with nanometer-thick metal oxide layers. The platform's two claimed technical capabilities are stability at temperatures up to 70°C without refrigeration, eliminating cold-chain requirements, and timed antigen/adjuvant release for up to six months post-injection, enabling multi-dose regimens to be delivered as a single shot. Manufacturing has been demonstrated at 10,000–100,000 doses per run using commercially available equipment and GRAS ingredients.

VitriVax operates as a B2B technology licensor and contract R&D provider rather than a vaccine manufacturer. Revenue is generated through three mechanisms: technology licensing to pharmaceutical partners (Soligenix for the RiVax ricin vaccine currently in Phase 1, and Serum Institute of India for a next-generation rabies vaccine), multi-year government contracts (notably a five-year, $29 million DTRA award for single-shot melioidosis and glanders vaccines), and non-dilutive grant funding from global health organizations (over $24.6M from the Bill & Melinda Gates Foundation and $5M from CEPI). The company targets three customer segments: clinical- and commercial-stage pharmaceutical and vaccine developers seeking thermostable or single-dose reformulations, government and defense health agencies focused on biodefense stockpiling and field deployment, and global health organizations addressing immunization gaps in low- and middle-income countries.

The company is venture-backed, with Adjuvant Capital having led the Series A in 2021 and co-led a $17.25 million Series B in October 2025 alongside RA Capital Management. Following the Series B and a $9.9 million Gates Foundation GMP scale-up grant, VitriVax signed a 31,465-square-foot lease at BioMed Realty's Flatiron Park campus in Boulder in March 2026 to expand its headquarters. The company remains pre-commercial in terms of product sales, with no disclosed revenue, and its near-term value creation is tied to advancing licensee programs through clinical milestones and converting additional anchors into recurring licensing or royalty arrangements.

Short descriptiontext

VitriVax is a Boulder, Colorado-based formulation technology company that licenses its proprietary ALTA® platform — combining spray drying and atomic layer deposition — to pharmaceutical, government, and global health partners seeking thermostable, single-dose vaccine formulations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBoulder, United States
HQ citystring
Boulder
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
vaccine formulation technology, thermostable vaccine platform, single-dose vaccine delivery, atomic layer deposition, vaccine stabilization technology
Industry2 codes
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAJ
Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
Product category
Vaccine Formulation Technology
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Technology Licensing
TypeLicensing Royalties
Description

Licensing ALTA® technology platform to pharmaceutical and biotech companies for vaccine formulation. Partners include Soligenix (RiVax thermostable ricin vaccine).

vitrivaxbio.com
2Government Contracts
TypeOthers
Description

Multi-year contracts from government agencies including $29M DTRA contract for melioidosis/glanders vaccine development

vitrivaxbio.com
3Research Grants
TypeGrants Donations
Description

Non-dilutive funding from foundations (Gates Foundation, CEPI) supporting platform development and specific vaccine programs

biospace.com
4Equity Financing
TypeOthers
Description

Institutional venture capital funding including Series A (Adjuvant Capital) and Series B ($17.25M co-led by Adjuvant Capital and RA Capital Management)

biospace.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1ALTA® Platform
Description

Atomic Layering Thermostable Antigen and Adjuvant technology platform enabling thermostable, single-shot vaccines without cold-chain storage requirements.

vitrivaxbio.com
Core offering1 text field

VitriVax provides the ALTA® vaccine formulation platform, which combines spray drying (encapsulating antigens in a sugar-glass matrix for thermal/chemical protection) with atomic layer deposition (nanometer-thick metal oxide coatings for timed antigen/adjuvant release). The platform enables thermostable, single-dose vaccine formulations that remain stable up to 70°C and convert multi-dose regimens into a single injection, addressing cold-chain and compliance barriers to global vaccine access.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Vaccine stability up to 70°C for extended periods
+3 more records
Product overview1 text field

VitriVax offers a single unified technology platform called ALTA® (Atomic Layering Thermostable Antigen and Adjuvant) that provides vaccine formulation services rather than standalone software products. The ALTA® platform combines spray drying technology with atomic layer deposition (ALD) to create thermostable, single-dose vaccine formulations. The company partners with vaccine developers to reformulate their existing vaccines using this platform, eliminating cold-chain storage requirements and enabling multi-dose delivery in a single injection.

Product and service1 record
1ALTA® (Atomic Layering Thermostable Antigen and Adjuvant) Platform
CategoryVaccine Formulation Technology Platform
Description

A proprietary vaccine formulation technology platform that combines spray drying (encapsulating antigens in a sugar-glass matrix) with atomic layer deposition (nanometer-thick metal oxide coatings) to produce thermostable, single-shot vaccines. Used by VitriVax to reformulate partner vaccine candidates, enabling stability up to 70°C and single-injection delivery of multi-dose regimens via timed antigen/adjuvant release.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierSupportingTypeOthersAnnounced on2026-03-24
Description

Landlord and life sciences campus provider. VitriVax leased 31,465 sq ft at Flatiron Park campus in Boulder. Long-term partnership within BioMed Realty's life science innovation ecosystem.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-28
Description

Partnership to explore adapting RabiVax-S (current 3-dose rabies vaccine) using ALTA® platform for single-administration, thermostable next-generation rabies vaccine. Includes preclinical, scale-up, and GLP safety-toxicity studies.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2023-07-19
Description

Research partner alongside DTRA for melioidosis and glanders vaccine development program.

Strategic tierSupportingTypeImplementation/ SI/ Consulting PartnerAnnounced on2023-07-19
Description

Support team for DTRA program with Bp vaccine development, government program management, and contract compliance expertise.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2019-12-21
Description

Licensee of VitriVax's thermostability technology for RiVax®, a heat-stable ricin toxin vaccine in Phase 1 clinical trials.

Strategic tierFoundationalTypeStrategic or Co-development PartnerAnnounced on2016-11-04
Description

Foundational research collaboration in CU Boulder labs (Garcea, Randolph, Weimer) leading to ALTA® technology development. Gates Foundation $1.1M grant for next-generation vaccine research.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Soligenix is a direct peer and active licensee of VitriVax's ALTA technology, using it to develop RiVax (thermostable ricin vaccine in Phase 1) and other vaccine candidates. Both companies operate in the thermostable vaccine formulation space and share a customer/partner overlap in biodefense.

TypeEmerging player
Description

Stablepharma develops a thermostable vaccine platform (StablevaX) using trehalose-based stabilization — directly addressing the same cold-chain problem VitriVax solves with ALTA, though with a different chemical mechanism. Comparable as a horizontal thermostability platform targeting the same vaccine developer customers.

TypeEmerging player
Description

Vaxxas develops high-density microarray patch (HD-MAP) vaccine delivery technology with the goal of thermostable, single-dose administration — a parallel technical approach to ALTA targeting similar global health and pharmaceutical partners (including Gates Foundation funding).

TypeEmerging player
Description

Matinas developed the LNC (lipid nanocrystal) oral delivery platform to enable oral administration of vaccines and therapeutics, addressing needle-free and cold-chain challenges relevant to global health. Comparable as a platform enabling alternative vaccine delivery routes.

TypeEmerging player
Description

PharmaJet provides needle-free injection systems (Tropis and Stratis) for vaccines, addressing both dose-sparing and administration challenges — adjacent to VitriVax's mission of enabling single-dose, easier-to-administer vaccine regimens in global health settings.

TypeEmerging player
Description

Adjuvance develops semi-synthetic saponin adjuvant technology (TQL1055) for vaccine formulation — directly comparable to VitriVax's adjuvant-formulation expertise (ALTA combines antigen + adjuvant), and serves the same pharmaceutical vaccine developer customer base.

TypeEmerging player
Description

Inventprise develops novel conjugate vaccine platform technology with Bill & Melinda Gates Foundation backing, targeting global health diseases — comparable as a vaccine platform company serving the same Gates/CEPI ecosystem of funders and global health customers as VitriVax.

TypeEmerging player
Description

VBI Vaccines develops enveloped virus-like particle (eVLP) vaccine platform technology (e.g., Sci-B-Vac for hepatitis B) and is similarly structured as a platform-focused vaccine company partnering with global health and pharmaceutical organizations — comparable in business model and target customers.

TypeBroad incumbent
Description

Novavax is a larger established vaccine platform company built around recombinant protein nanoparticle technology (Matrix-M adjuvant), with an approved COVID vaccine. Serves as a broad incumbent in vaccine platform technology and represents a potential strategic acquirer of VitriVax.

TypeBroad incumbent
Description

Catalent is a major vaccine and biologic CDMO with extensive formulation, fill-finish, and thermostable development capabilities — broadly comparable as a development partner and scale-up service for the same pharmaceutical vaccine customers VitriVax serves, though much larger in scope.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

VitriVax

Vaccine Formulation Technologyvitrivaxbio.com

VitriVax is a Boulder, Colorado-based formulation technology company that licenses its proprietary ALTA® platform — combining spray drying and atomic layer deposition — to pharmaceutical, government, and global health partners seeking thermostable, single-dose vaccine formulations.

What VitriVax does

VitriVax is a privately held formulation technology company based in Boulder, Colorado, founded in 2014 out of the University of Colorado Boulder laboratories of co-founders Dr. Robert Garcea (virology) and Dr. Theodore Randolph (chemical engineering). The company develops and licenses a single proprietary platform — ALTA® (Atomic Layering Thermostable Antigen and Adjuvant) — that combines spray drying, which encapsulates antigens in a sugar-glass matrix, with atomic layer deposition (ALD), which coats the resulting microparticles with nanometer-thick metal oxide layers. The platform's two claimed technical capabilities are stability at temperatures up to 70°C without refrigeration, eliminating cold-chain requirements, and timed antigen/adjuvant release for up to six months post-injection, enabling multi-dose regimens to be delivered as a single shot. Manufacturing has been demonstrated at 10,000–100,000 doses per run using commercially available equipment and GRAS ingredients.

VitriVax operates as a B2B technology licensor and contract R&D provider rather than a vaccine manufacturer. Revenue is generated through three mechanisms: technology licensing to pharmaceutical partners (Soligenix for the RiVax ricin vaccine currently in Phase 1, and Serum Institute of India for a next-generation rabies vaccine), multi-year government contracts (notably a five-year, $29 million DTRA award for single-shot melioidosis and glanders vaccines), and non-dilutive grant funding from global health organizations (over $24.6M from the Bill & Melinda Gates Foundation and $5M from CEPI). The company targets three customer segments: clinical- and commercial-stage pharmaceutical and vaccine developers seeking thermostable or single-dose reformulations, government and defense health agencies focused on biodefense stockpiling and field deployment, and global health organizations addressing immunization gaps in low- and middle-income countries.

The company is venture-backed, with Adjuvant Capital having led the Series A in 2021 and co-led a $17.25 million Series B in October 2025 alongside RA Capital Management. Following the Series B and a $9.9 million Gates Foundation GMP scale-up grant, VitriVax signed a 31,465-square-foot lease at BioMed Realty's Flatiron Park campus in Boulder in March 2026 to expand its headquarters. The company remains pre-commercial in terms of product sales, with no disclosed revenue, and its near-term value creation is tied to advancing licensee programs through clinical milestones and converting additional anchors into recurring licensing or royalty arrangements.

VitriVax firmographics

Firmographics
Name
VitriVax
Legal name
VitriVax, Inc.
Website
https://vitrivaxbio.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Short description
VitriVax is a Boulder, Colorado-based formulation technology company that licenses its proprietary ALTA® platform — combining spray drying and atomic layer deposition — to pharmaceutical, government, and global health partners seeking thermostable, single-dose vaccine formulations.
Ownership category
akta.pro rank

VitriVax industry classification

Industry
Product category
Vaccine Formulation Technology
akta.pro industry
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAJ
Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Vaccine formulation technology
  • Thermostable vaccine platform
  • Single-dose vaccine delivery
  • Atomic layer deposition
  • Vaccine stabilization technology

Where VitriVax is headquartered

Location

Headquarters

HQ city
Boulder
HQ country
United States
HQ region
North America

Offices1 record

Markets served

VitriVax business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Technology Licensing: Licensing ALTA® technology platform to pharmaceutical and biotech companies for vaccine formulation. Partners include Soligenix (RiVax thermostable ricin vaccine).
  2. Government Contracts: Multi-year contracts from government agencies including $29M DTRA contract for melioidosis/glanders vaccine development
  3. Research Grants: Non-dilutive funding from foundations (Gates Foundation, CEPI) supporting platform development and specific vaccine programs
  4. Equity Financing: Institutional venture capital funding including Series A (Adjuvant Capital) and Series B ($17.25M co-led by Adjuvant Capital and RA Capital Management)

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

VitriVax product offering

Product offering

Core offering

VitriVax provides the ALTA® vaccine formulation platform, which combines spray drying (encapsulating antigens in a sugar-glass matrix for thermal/chemical protection) with atomic layer deposition (nanometer-thick metal oxide coatings for timed antigen/adjuvant release). The platform enables thermostable, single-dose vaccine formulations that remain stable up to 70°C and convert multi-dose regimens into a single injection, addressing cold-chain and compliance barriers to global vaccine access.

Product overview

VitriVax offers a single unified technology platform called ALTA® (Atomic Layering Thermostable Antigen and Adjuvant) that provides vaccine formulation services rather than standalone software products. The ALTA® platform combines spray drying technology with atomic layer deposition (ALD) to create thermostable, single-dose vaccine formulations. The company partners with vaccine developers to reformulate their existing vaccines using this platform, eliminating cold-chain storage requirements and enabling multi-dose delivery in a single injection.

Differentiator

Problem solved

Functional benefit

Brands

  • ALTA® Platform: Atomic Layering Thermostable Antigen and Adjuvant technology platform enabling thermostable, single-shot vaccines without cold-chain storage requirements.

Products and services

  • ALTA® (Atomic Layering Thermostable Antigen and Adjuvant) Platform A proprietary vaccine formulation technology platform that combines spray drying (encapsulating antigens in a sugar-glass matrix) with atomic layer deposition (nanometer-thick metal oxide coatings) to produce thermostable, single-shot vaccines. Used by VitriVax to reformulate partner vaccine candidates, enabling stability up to 70°C and single-injection delivery of multi-dose regimens via timed antigen/adjuvant release.

Quantifiable outcome

  • Vaccine stability up to 70°C for extended periods
  • +3 more outcomes

Companies that use VitriVax

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

VitriVax technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

VitriVax partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered supporting, core and foundational.

  • BioMed RealtysupportingOthers · 24 March 2026Landlord and life sciences campus provider. VitriVax leased 31,465 sq ft at Flatiron Park campus in Boulder. Long-term partnership within BioMed Realty's life science innovation ecosystem.
  • Serum Institute of IndiacoreStrategic or Co-development Partner · 28 April 2025Partnership to explore adapting RabiVax-S (current 3-dose rabies vaccine) using ALTA® platform for single-administration, thermostable next-generation rabies vaccine. Includes preclinical, scale-up, and GLP safety-toxicity studies.
  • University of Nevada, RenosupportingStrategic or Co-development Partner · 19 July 2023Research partner alongside DTRA for melioidosis and glanders vaccine development program.
  • Latham BioPharm GroupsupportingImplementation/ SI/ Consulting Partner · 19 July 2023Support team for DTRA program with Bp vaccine development, government program management, and contract compliance expertise.
  • SoligenixcoreOEM/ Whitelabel/ Licensing Partner · 21 December 2019Licensee of VitriVax's thermostability technology for RiVax®, a heat-stable ricin toxin vaccine in Phase 1 clinical trials.
  • University of Colorado BoulderfoundationalStrategic or Co-development Partner · 4 November 2016Foundational research collaboration in CU Boulder labs (Garcea, Randolph, Weimer) leading to ALTA® technology development. Gates Foundation $1.1M grant for next-generation vaccine research.

Scale indicators8 records

Recent moves7 records

Expansion highlights4 records

VitriVax competitors and assessment

Company assessment

Direct peers

  • Soligenix: Soligenix is a direct peer and active licensee of VitriVax's ALTA technology, using it to develop RiVax (thermostable ricin vaccine in Phase 1) and other vaccine candidates. Both companies operate in the thermostable vaccine formulation space and share a customer/partner overlap in biodefense.

Emerging players

  • Stablepharma: Stablepharma develops a thermostable vaccine platform (StablevaX) using trehalose-based stabilization — directly addressing the same cold-chain problem VitriVax solves with ALTA, though with a different chemical mechanism. Comparable as a horizontal thermostability platform targeting the same vaccine developer customers.
  • Vaxxas: Vaxxas develops high-density microarray patch (HD-MAP) vaccine delivery technology with the goal of thermostable, single-dose administration — a parallel technical approach to ALTA targeting similar global health and pharmaceutical partners (including Gates Foundation funding).
  • Matinas BioPharma: Matinas developed the LNC (lipid nanocrystal) oral delivery platform to enable oral administration of vaccines and therapeutics, addressing needle-free and cold-chain challenges relevant to global health. Comparable as a platform enabling alternative vaccine delivery routes.
  • PharmaJet: PharmaJet provides needle-free injection systems (Tropis and Stratis) for vaccines, addressing both dose-sparing and administration challenges — adjacent to VitriVax's mission of enabling single-dose, easier-to-administer vaccine regimens in global health settings.
  • Adjuvance Technologies: Adjuvance develops semi-synthetic saponin adjuvant technology (TQL1055) for vaccine formulation — directly comparable to VitriVax's adjuvant-formulation expertise (ALTA combines antigen + adjuvant), and serves the same pharmaceutical vaccine developer customer base.
  • Inventprise: Inventprise develops novel conjugate vaccine platform technology with Bill & Melinda Gates Foundation backing, targeting global health diseases — comparable as a vaccine platform company serving the same Gates/CEPI ecosystem of funders and global health customers as VitriVax.
  • VBI Vaccines: VBI Vaccines develops enveloped virus-like particle (eVLP) vaccine platform technology (e.g., Sci-B-Vac for hepatitis B) and is similarly structured as a platform-focused vaccine company partnering with global health and pharmaceutical organizations — comparable in business model and target customers.

Broad incumbents

  • Novavax: Novavax is a larger established vaccine platform company built around recombinant protein nanoparticle technology (Matrix-M adjuvant), with an approved COVID vaccine. Serves as a broad incumbent in vaccine platform technology and represents a potential strategic acquirer of VitriVax.
  • Catalent (Novo Holdings): Catalent is a major vaccine and biologic CDMO with extensive formulation, fill-finish, and thermostable development capabilities — broadly comparable as a development partner and scale-up service for the same pharmaceutical vaccine customers VitriVax serves, though much larger in scope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

VitriVax social profiles

Digital presence

VitriVax financial estimates

Financial estimate

Revenue estimate

Valuation estimate

VitriVax leadership team

Management profile

Number of profiles

Profiles10 records

VitriVax funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

VitriVax M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VitriVax

What does VitriVax do?

VitriVax provides the ALTA® vaccine formulation platform, which combines spray drying (encapsulating antigens in a sugar-glass matrix for thermal/chemical protection) with atomic layer deposition (nanometer-thick metal oxide coatings for timed antigen/adjuvant release). The platform enables thermostable, single-dose vaccine formulations that remain stable up to 70°C and convert multi-dose regimens into a single injection, addressing cold-chain and compliance barriers to global vaccine access.

Is VitriVax a public or private company?

VitriVax is a private company. It is classified as venture growth investor backed and is currently operating.

When was VitriVax founded?

VitriVax was founded in 2014. It employs 51 to 100 people.

Where is VitriVax based?

VitriVax is headquartered in Boulder, United States, in the North America region.

How does VitriVax make money?

Four revenue lines are on record. Technology Licensing is the primary driver. The others are government Contracts, research Grants and equity Financing.

Who are VitriVax's main competitors?

Soligenix is listed as a direct peer. Emerging players are Stablepharma, Vaxxas, Matinas BioPharma, PharmaJet, Adjuvance Technologies, Inventprise and VBI Vaccines. Broad incumbents are Novavax and Catalent (Novo Holdings).

Does VitriVax have an API?

No public API is recorded for VitriVax.

What industry is VitriVax in?

VitriVax's product category is Vaccine Formulation Technology. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA), with a secondary code of HLAAAEAJ, Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable).

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Startup ResearcherVitriVax Closes $87 Million Series C FinancingVitriVax closed an oversubscribed $87 million Series C financing led by F-Prime, NEA, RA Capital Management, and Sanofi Ventures, with Eli Lilly and others participating. The capital will advance its Lyme disease vaccine candidate into first-in-human testing and support pipeline expansion via the ALTA platform.citybizVitriVax Raises $87 Million Series C to Advance Lyme Disease Vaccine DevelopmentVitriVax raised $87 million in an oversubscribed Series C to advance its Lyme disease vaccine into first-in-human testing. The funding, co-led by F-Prime, NEA, RA Capital, and Sanofi Ventures, will also expand its proprietary ALTA platform for single-dose vaccines. The company plans to continue partnered programs with Gates Foundation, CEPI, and the U.S. Department of Defense.Dealroom.coVitriVax raises $87M Series C to chase first Lyme disease vaccine | Dealroom NewsVitriVax raised $87 million in a Series C round, a five-fold increase from its $17.25 million Series B. The funding targets a Lyme vaccine, with no approved product and Pfizer-Valneva's candidate facing regulatory uncertainty. VitriVax aims to compete with Pfizer and Moderna's clinical-stage candidates.CostarVaccine tech developer's expansion is latest sign of nation's life science recoveryVitriVax, a Boulder-based vaccine technology developer founded in 2014, signed a more than 31,450-square-foot lease at Blackstone's BioMed Realty's Flatiron Park campus to expand its headquarters, following a recent funding round aimed at improving vaccine access and immunization coverage. The expansion signals growing demand for life science real estate as the U.S. sector recovers from post-pandemic headwinds, with national vacancy rates at about 27% despite 61 million square feet of available biotech real estate still on the market. Multiple other biotech companies, including CordenPharma, Natera, Zealand Pharma, Lila Sciences, and TransMedics, are also expanding their footprints across major U.S. biotech hubs, suggesting broader sector recovery.YahooNext-Generation Vaccine Platform Technology Company VitriVax Joins BioMed Realty’s Roster of Innovative Tenants at Flatiron Park in Boulder, ColoradoBioMed Realty announced that VitriVax, a vaccine platform technology company, has leased 31,465 square feet at 5500 Central Avenue within Flatiron Park in Boulder, Colorado. VitriVax will use the space to advance its proprietary Atomic Layering Thermostable Antigen and Adjuvant (ALTA®) platform, which enables thermostable, single-shot vaccine formulations without cold-chain storage requirements. The company stated that proximity to the University of Colorado research community and talent pipeline were key factors in remaining in Boulder rather than relocating.PharmiWeb.comNext-Generation Vaccine Platform Technology Company VitriVax Joins BioMed Realty’s Roster of Innovative Tenants at Flatiron Park in Boulder, ColoradoBioMed Realty announced that vaccine platform technology company VitriVax has leased 31,465 square feet at 5500 Central Avenue within Flatiron Park in Boulder, Colorado, expanding its presence at the campus. VitriVax will use the space to advance its proprietary Atomic Layering Thermostable Antigen and Adjuvant (ALTA®) platform, which enables thermostable, single-shot vaccine formulations designed to eliminate cold-chain storage requirements. The lease represents VitriVax's decision to remain in Boulder near the University of Colorado research community as a long-term partnership within BioMed Realty's life science innovation ecosystem.PatsnapDrug pipelines, Patents, Clinical trialsVitriVax, Inc. announced it raised $17.25 million in Series B financing co-led by Adjuvant Capital and RA Capital Management to advance its ALTA® vaccine formulation platform. The funding supports the continued development and commercialization of this thermostable, single-shot technology designed to eliminate cold-chain dependencies for vaccines.LinkedInVitriVaxVitriVax, Inc. has been awarded a two-year, $9.9 million grant from the Gates Foundation to support the scale-up of its ALTA® technology toward Phase 1-ready GMP manufacturing. This funding is crucial for advancing the platform to prepare for Phase 1 clinical trials aimed at producing thermostable, single-shot vaccines. The project emphasizes building GMP-compliant manufacturing capacity to ensure effective vaccines can reach global populations.SecSEC FORM DVitriVax, Inc., a Delaware-incorporated biotechnology company headquartered in Boulder, Colorado, filed a Form D notice with the SEC for an exempt offering of equity securities under Rule 506(b), with the first sale occurring on June 30, 2025. The company is seeking to raise up to $37,148,654, of which $29,430,356 has already been sold to 83 investors with $7,718,298 remaining. The filing was signed by Romulo Colindres as President/CEO on November 17, 2025.KofirmKO Client VitriVax Closes $17.25 Million Series BVitriVax, a vaccine formulation technology company, has closed a $17.25 million Series B financing round co-led by Adjuvant Capital and RA Capital Management. The funding will support the advancement of its ALTA® thermostable vaccine platform through the next phase of clinical and regulatory development.